References

  1. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38(10):1478-1484.
  2. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis. 2008;12(6):e77-e83.
  3. Gallagher KM, Juhasz M, Harris NS, Teshale EH. Predictors of influenza vaccination in HIV-infected patients in the United States, 1990-2002. J Infect Dis. 2007;196(3):339-346.
  4. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult_OI.pdf. Accessed June 29, 2017.
  5. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318.
  6. Kim DK, Bridges CB, Harriman KH. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older – United States, 2016. Am J Transplant. 2016;16(6):1930-1932.
  7. Centers for Disease Control and Prevention. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Accessed June 29, 2017.
  8. Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947.
  9. Weinberg A, Muresan P, Richardson KM, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS One. 2015;10(4):e0122431.
  10. Money DM, Moses E, Blitz S, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34(40):4799-4806.
  11. Landrum ML, Huppler HK, Ganesan A, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27(34):4731-4738.
  12. Zoufaly A, An der HM, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2011;203(3):364-371.
  13. Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6(3):e17758.
  14. McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013;158(1):19-26.
  15. El Sahly HM, Davis C, Kotloff K, et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012;205(5):703-712.
  16. Hakim H, Allison KJ, Van de Velde LA, et al. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016;34(27):3141-3148.
  17. Johnston JA, Tincher LB, Lowe DK. Booster and higher antigen doses of inactivated influenza vaccine in HIV-infected patients. Ann Pharmacother. 2013;47(12):1712-1716.
  18. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092-4102.
  19. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262(6):779-783.
  20. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1-54.
  21. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015;33(36):4565-4571.
  22. Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin Vaccine Immunol. 2016;23(3):228-235.
  23. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1-28.
  24. MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons – Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(43):1189-1194.
  25. Cohen CR, Moscicki AB, Scott ME, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS. 2010;24(13):2069-2074.
  26. Centers for Disease Control and Prevention (CDC). Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men – New York City, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;61(51-52):1048.
  27. Nanduri S, Foo C, Ngo V, et al. Outbreak of serogroup C meningococcal disease primarily affecting men who have sex with men – Southern California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):939-940.
  28. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1176.
  29. Kim DK, Bridges CB, Harriman KH. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older–United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(4):91-92.
  30. Glesby MJ, Watson W, Brinson C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015;212(1):18-27.
  31. Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015;29(11):1345-1354.
  32. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33.
  33. Mena G, Garcia-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother. 2015;11(11):2582-2598.
  34. Wolters B, Muller T, Ross RS, et al. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin. 2009;5(4):248-253.
  35. Abzug MJ, Warshaw M, Rosenblatt HM, et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009;200(6):935-946.
  36. Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283-1291.
  37. Launay O, Van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305(14):1432-1440.
  38. Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409.
  39. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-1396.
  40. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/Adult_OI.pdf. Accessed June 29, 2017.
  41. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
  42. Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304.
  43. Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209(8):1165-1173.
  44. Toft L, Tolstrup M, Muller M, et al. Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccin Immunother. 2014;10(5):1147-1154.
  45. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705-719.
  46. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011;7(12):1359-1373.
  47. Strikas RA. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years–United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(4):93-94.
  48. Cheetham TC, Marcy SM, Tseng HF, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865-873.
  49. Gagliardi AM, Andriolo BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2016;3:CD008858.
  50. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729-731.
  51. Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial [Abstract 96].  19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, Washington.
  52. Le P, Rothberg MB. Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis. J Gen Intern Med. 2016;
  53. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096.
  54. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032.
  55. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375:229-239.
  56. Askling HH. Pre-travel advice to the most immunocompromised; Trying to guide where evidence is scarce. Travel Med Infect Dis. 2015;13(1):6-7.
  57. Askling HH, Dalm VA. The medically immunocompromised adult traveler and pre-travel counseling: status quo 2014. Travel Med Infect Dis. 2014;12(3):219-228.
  58. Aung AK, Trubiano JA, Spelman DW. Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ transplant and haematopoeitic stem cell transplant recipients): A review. Travel Med Infect Dis. 2015;13(1):31-47.
  59. Centers for Disease Control (CDC). Immunocompromised travelers. https://wwwnc.cdc.gov/travel/yellowbook/2016/advising-travelers-with-specific-needs/immunocompromised-travelers. Accessed June 29, 2017.
  60. Pacanowski J, Lacombe K, Campa P, et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. JAIDS. 2012;59(4):360-367.
  61. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48(5):659-666.
  62. Keddy KH, Sooka A, Smith AM, et al. Typhoid fever in South Africa in an endemic HIV setting. PLoS One. 2016;11(10):e0164939.
  63. Manfredi R, Donzelli C, Talo S, Guzman SM, Chiodo F. Typhoid fever and HIV infection: a rare disease association in industrialized countries. Int J Infect Dis. 1998;3(2):105-108.
  64. Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine–Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(11):305-308.
  65. Banda R, Yambayamba V, Lalusha BD, Sinkala E, Kapulu MC, Kelly P. Safety of live, attenuated oral vaccines in HIV-infected Zambian adults: oral vaccines in HIV. Vaccine. 2012;30(38):5656-5660.
  66. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.
  67. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention–United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1-28.
  68. Centers for Disease Control and Prevention (CDC). Japanese encephalitis surveillance and immunization–Asia and the Western Pacific, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(33):658-662.
  69. Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(20):661-663.
  70. Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(45):898-900.
  71. Fischer M, Lindsey N, Staples JE, Hills S, Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-1):1-27.
  72. Centers for Disease and Control and Prevention (CDC). Immunization strategies for healthcare practices and providers. https://www.cdc.gov/vaccines/pubs/pinkbook/strat.html. Accessed June 29, 2017.